市場調查報告書
商品編碼
1069394
缺血性中風市場 - 基於流行病學的當前市場價值(2021年)與預測(到2030年),競爭新藥的價格策略,交易價值評估,r-NPV,開發平台藥物的分析(2022年前半期)Ischemic Stroke - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022 Report |
本報告提供全球缺血性中風市場相關調查,提供市場概要,以及2030年前的預測,開發平台趨勢,競爭策略等資訊。
GervanoRA's pipeline analysis and opportunity assessment report, "Ischemic Stroke - Epidemiology Based Current (2021) and Forecasted (Till 2030) Market Values, Competitor New Drugs Pricing Strategies, Deal Worth Assessments, r-NPV and Pipeline Drugs Analytics H1 2022" analysed and assessed Ischemic Stroke pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Ischemic Stroke drugs industry.
The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analytics to provide in depth insights about the market dynamics and ongoing R&D in the Ischemic Stroke area. The report provides detailed insights about all the pipeline molecules in different stages of development and all the companies which are actively involved in Ischemic Stroke drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Analytics by Stage of development, Pipeline Analytics by Route of Administration, Pipeline Analytics by Geography, Pipeline Analytics by Mechanism of Action, Pipeline Analytics by Drug Class, Pipeline Analytics by Molecule Type, Pipeline Analytics by Molecule Target and Pipeline Analytics by Company Type.
The report delivers an in-depth understanding of the Ischemic Stroke historical and forecasted epidemiology based market trends Worldwide, the United States, EU8 (Poland, Spain, Switzerland, Sweden, Italy, Germany, Austria, France), United Kingdom and China. A detailed analytics on the Current Ischemic Stroke Market (2021) and the Forecasted Ischemic Stroke Market until the year 2030 for the regions have been provided.
Growth opportunities in the report have been provided by performing a competitive and comparative analysis on the Emerging companies in the domain based on In-Licensing opportunities, Out-Licensing opportunities, Corporate Partnering opportunities and funding opportunities. The report even aimed to conduct the Risk-Adjusted Net Present Value (RNPV) Analysis with its Excel based r-NPV analysis model to help companies in licensing negotiations, technology valuations and pipeline asset valuation and establishing the value for licensing deal. It also aims to provide the sales potential of the drugs along with the new drugs pricing and pricing strategies.
Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:
Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.